Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-09-04
2007-09-04
Campbell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S231100, C424S093100, C435S069300
Reexamination Certificate
active
08459141
ABSTRACT:
Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of truncated, membrane-free derivatives of a membrane-bound polypeptide from the pathogen. These polypeptides when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.
REFERENCES:
patent: 4317811 (1982-03-01), Bertland et al.
patent: 4374127 (1983-02-01), Larson et al.
patent: 4442205 (1984-04-01), Hamer et al.
patent: 4593002 (1986-06-01), Dulbecco
patent: 4618578 (1986-10-01), Burke et al.
patent: 4818694 (1989-04-01), Watson et al.
patent: 4855224 (1989-08-01), Berman et al.
patent: 4891315 (1990-01-01), Watson et al.
patent: 5314808 (1994-05-01), Tiollais et al.
patent: 1745283 (1984-02-01), None
patent: 0001365 (1979-04-01), None
patent: 0101655 (1984-02-01), None
patent: 0133063 (1985-02-01), None
patent: 0168662 (1986-01-01), None
patent: 0170169 (1986-02-01), None
patent: 0243155 (1987-10-01), None
patent: 2105344 (1983-03-01), None
patent: 8302897 (1983-09-01), None
patent: 8504587 (1985-10-01), None
Berman, et al, 1988, “Expression of Membrane- . . . ” J. Virology 62(9): 3135-3142.
Rose, et al, 1982, “Expression From Cloned cDNA of . . . ” Cell 30 : 753-762.
Watson, et al, 1982, “Herpes Simplex Virus . . . ” Science 218: 381-384.
Chan, 1983, “Protective Immunization of Mice With . . . ” Immunol. 49: 343-352.
Kantman, et al, 1982, “Construction of a Modular Dihydrofolate . . . ” Molec. & Cell Biol. 2(11): 1304-1319.
Mester et al.; The Mouse and understanding immunity . . . ; Rev. of Inf. Dis.; 13 (supp. 11); S935-S945, 1991.
Paul Fundamental Immunology, Raven Press, New York, NY; 1993; 3rd Edition, p. 251.
Yang et al. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. Journal of Virology (2001) vol. 75, pp. 1165-1171.
Dundarov et al. Immunotherapy with inactivated polyvalent herpes vaccines. Development Biolgical Standard. 1982;52:351-8.
Watson et al., “Herpes Simplex Virus Type-1Glycoprotein D Gene: Nucleotide Sequence and Expression inEscherichia coli” Science, 218:381-384 (Oct. 22, 1982).
Rose et al., “Expression from Cloned cDNA of Cell-Surface Secreted Forms of the Glycoprotein of Vesicular Stomatitis Virus in Eucaryotic Cells”Cells, 30:753-762 (Oct. 1982).
Kaufman et al., “Construction of a Modular Dihydrofolate Reductase cDNA Gene: Analysis of Signals Utilized for Efficient Expression,”Molecular and Cellular Biology, 3(11):1304-1319 (1982).
Chan, “Protective Immunization of Mice with Specific HSV-1 Glycoproteins,”Immunology, 49:343-352 (1983).
Dreesman et al., “Antibody to Hepatitis B Surface Antigen After a Single Inoculation of Uncoupled Synthetic HbsAg Peptides,”Nature, 295:158-160 (1982).
Middleton et al, “Expression of Cloned Herpesvirus Genes: Detection of Nuclear Antigens from Herpes Simplex Virus Type 2 Inverted Repeat Regions in Transfected Mouse Cells,”Journal of Virology, 43(3):1091-1101 (Sep. 1982).
Lee et al., “Expression of Herpes Simplex Virus Glycoprotein C From a DNA Fragment Inserted into the Thymidine Kinase Gene of this Virus,”PNAS, USA, 79:6612-6616 (Nov. 1982).
Zoler et al., “Scientists Engineer Proteins for Cellular Export,”Bio/Technology146-147 (Apr. 1983).
Spear, P.G., “Cell Membranes and Viral Envelopes,”Herpes Viruses, 2:709-150 (1980).
Balachandran et al., “Protection Against Lethal Challenge of BALB/c Mice by Passive Transfer of Monoclonal Antibodies to Five Glycoproteins of Herpes Simplex Virus Type 2,”Infect. Immun., 37:1132-1137 (1982).
Dix et al., “Use of Monoclonal Antibody Directed Against Herpes Simplex Virus Glycoproteins to Protect Mice Against Acute Virus-Induced Neurological Disease,”Infect. Immun., 34:192-199 (1982).
Gething et al., “Molecular and Chemical Basis of Virus Virulence and Immunology,”Modern Approaches to Vaccines, (pub. Cold Spring Harbor Laboratories) Proceedings of Meetings at Cold Spring Harbor: 262-268.
Alt et al, “Synthesis of Secreted and Membrane-Bound Immunoglobin Mu Heavy Chains is Directed by mRNAs that Differ at Their 3′ Ends,”Cell, 20:293-301 (1980).
Early et al., “Two mRNAs Can Be Produced From a Single Immunoglobulin u Gene by Alternative RNA Processing Pathways,”Cell, 20:313-319 (1980).
Cheng et al., “Structure of Gene for Membrane and Secreted Murine IgD Heavy Chains,”Nature, 296:410-415 (1982).
Rogers et al., “Gene Segments Encoding Transmembrane Carboxyl Termini of Immunoglobulin Chains,”Cell, 26:19-27 (1981).
Mertz et al., “Double-Blind, Placebo-Controlled Trial of a Herpes Simplex Virus Type 2 Glycoprotein Vaccine in Persons at High Risk for Genital Herpes Infection,”Journal of Infectious Diseases, 161:653-660 (1989).
Schrier et al., “Type-Specific Delayed Hypersensitivity and Protective Immunity Induced by Isolated Herpes Simplex Virus Glycoprotein,”J. Immunol., 130(3):1413-1418 (Mar. 1983).
Wiley et al., Structural Identification of the Antibody-Binding Sites of Hong Kong Influenza Haemagglutinin and Their Involvement in Antigenic Variation,:Nature, 289:373-378 (1981).
Gething et al., “Cell-Surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene,”Nature, 293:620-625 (1981).
Lusky et al., “Inhibition of SV40 Replication in Simian Cells by Specific pBR322 DNA Sequences,”Nature, 293:79-81 (1981).
Lasky et al., “Protection of Mice From Lethal Herpes Simplex Virus Infection by Vaccination with a Secreted Form of Cloned Glycoprotein D,”Bio/Technology, (Jun. 1984).
Cohen et al., “Localization and Synthesis of an Antigenic Determinant of Herpes Simplex Virus Glycoprotein D That Stimulates the Production of Neutralizing Antibody,”J. Virol., 49:102-108 (1984).
Dietzschold et al., “Synthesis of an Antigeic Determinant of the HSV gD That Stimulates the Induction of Virus-Neutralizing Antibodies and Confers Protection Against a Lethal Challenge of HSV,” 145-149.
Eisenberg et al., “Comparative Structural Analysis of Glycoprotein gD of Herpes Simplex Virus Types 1 and 2,”J. Virol., 35:428-434 (1980).
Webster's Ninth New Collegiate Dictionary (1983) p. 1301.
The American Heritage Dictionary, Second college Edition, (1991) p. 384.
Bay Area Bioscience Centre “Northern California's Bioscience Legacy” 1-33 (1991).
Hitzeman et al., “Expression of Hepatitis B Virus Surface Antigen in Yeast,”NAR 11, (9), 2745 (1983).
Wilson et al., “Structure of the Haemagglutinin Membrane Glycoprotein of Influenza Virus at 3 Å Resolution,”Nature 289, 366 (1981).
Kleid et al., “Cloned Viral Protein Vaccine for Foot-and-Mouth Disease: Responses in Cattle and Swine,”Science 214, 1125 (1981).
Rose et al., “Conditional Expression of the Vesicular Stomatitis Virus Glycoprotein Gene inEscherichia coli,”PNAS USA 78(11) (1981).
Brand et al., “Crystalline Antigen From the Influenza Virus Envelope,”Nature New Biology 238, 145.
Berman Phillip W.
Lasky Laurence A.
Beyer & Weaver, LLP
Campbell Bruce R.
Genentech Inc.
Haliday Emily M.
Kinsey Nicole
LandOfFree
Immunogenic composition based on a truncated derivative of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic composition based on a truncated derivative of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic composition based on a truncated derivative of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803097